LAS VEGAS, Feb. 11, 2025 /PRNewswire/ — DRI International is proud to announce the winners of the 2025 DRI Awards of Excellence for their achievements in the business continuity, disaster recovery, and crisis management fields.
“This year’s winners and finalists represent the best the resilience community has to offer. It’s a great honor to spotlight their achievements,” said Al Berman, DRI Treasurer and DRI Foundation President.
The Awards of Excellence were presented during the DRI2025 Awards Gala on Feb. 4 in Las Vegas, NV, at the Planet Hollywood Resort and Casino.
Consultant of the Year
Newcomer of the Year
Program Leader of the Year – Nonprofit
Program Leader of the Year – Private Sector
Response and Recovery of the Year
Team of the Year
Product/Service Provider of the Year
Lifetime Achievement Award
The Abu Dhabi Crisis Management Center (ADCMC) also received the DRI accreditation of “Resilient Enterprise” in recognition of the organization’s extraordinary commitment to preparedness and resiliency at the same ceremony. The ADCMC team accepting this award was led by H.E. Dr. Abdulla Rashid Hamarain Al Dhaheri, Executive Director of Response and Recovery Sector.
About DRI International:
Disaster Recovery Institute (DRI) International is the oldest and largest nonprofit that helps organizations around the world prepare for and recover from disasters by providing education, accreditation, and thought leadership in business continuity, disaster recovery, cyber resilience and related fields. Founded in 1988, DRI has certified 20,000+ resilience professionals in 110+ countries and at 95 percent of Fortune 100 companies.
SOURCE DRI International
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…